Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
COPENHAGEN, Denmark, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Zealand today announces that the company's CEO Britt Meelby Jensen will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, 14 January 2016 at the Westin St. Francis Hotel in San Francisco, California. The presentation will take place at 10:30 am PT (7.30 pm CET).
The presentation will focus on the acceleration of Zealand's strategic direction towards value generation - from peptide to patient - and will outline the company's pipeline and news flow outlook for 2016.
An audio webcast of the presentation will be available on the Investor Relations section of the company's website at www.zealandpharma.com .
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: [email protected]
About Zealand Pharma
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia(r) by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus(r)) which is on track for regulatory submission in the US in Q4 2015 and in the European Union in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand's business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
